柠檬酸镁(Magnesium citrate) - 在研适应症：肠道准备，原发性高血压，高血压_专利_临床

概要

基本信息

简介柠檬酸镁是一种由镁和柠檬酸以1:1的比例混合而成的小分子药物，被批准用于在结肠检查期间排除肠内容物和作为腹部手术的预处理泻药。柠檬酸镁的商品名有 Magcorol 和 Tectlol，该药物由 RMJ Holdings 制造，并于 1973 年 4 月 28 日首次在日本获得批准。柠檬酸镁的作用是将水分吸引到肠道并促进排便，从而清理肠道。它通常用于结肠镜检查或其他需要清洁肠道的医疗程序之前的肠道准备。柠檬酸镁可以液体或片剂形式在柜台销售，也可以药丸形式用作镁膳食补充剂。

药物类型

小分子化药

别名

Magnesium citrate (JAN/USP)、Magnesium citrate (RMJ Holdings)、Magnesium dicitrate

+ [6]

靶点-

作用机制-

治疗领域

其他疾病心血管疾病

在研适应症

肠道准备原发性高血压高血压

非在研适应症-

原研机构

RMJ Holdings, Inc.

在研机构

RMJ SGRpAHorii Pharmaceutical Ind., LTD.RMJ Holdings, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1973-04-28),

肠道准备

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

结构

分子式C6H8MgO7

InChIKeyROYPGAQNKYWYDI-UHFFFAOYSA-N

CAS号3344-18-1

查看全部结构式(2)

关联

12

项与柠檬酸镁相关的临床试验

JPRN-jRCTs041210067 / Not yet recruiting临床3期IIT

Efficacy and tolerability of elobixibat plus sodium picosulfate with magnesium citrate versus split dose 2-L polyethylene glycol with ascorbic acid for bowel preparation before outpatient colonoscopy:A multicenter, randomized controlled trial

开始日期2021-12-06

申办/合作机构-

NCT04930237 / WithdrawnN/AIIT

RELISTOR's Effects on Opioid-Induced Constipation in Postoperative 1-2 Level Anterior Lumbar Interbody Fusion Patients: A Case-Control Study

This will be a prospective case-control study of 40 patients undergoing 1-2 level ALIF procedures at Methodist Dallas Medical Center (MDMC). Patient records will be reviewed to identify details including demographics, comorbidities, procedure details, and the primary and secondary outcome metrics.

开始日期2021-07-01

申办/合作机构

Methodist Health System, Inc.

KCT0003662 / RecruitingN/A

Surgical site infection after bowel preparation for colorectal cancer with Sodium picosulfate and Magnesium citrate versus Clicool powder : A Randomized Non-inferiority Trial

开始日期2019-07-03

申办/合作机构

Kyungpook National University Medical Center

100 项与柠檬酸镁相关的临床结果

登录后查看更多信息

100 项与柠檬酸镁相关的转化医学

登录后查看更多信息

100 项与柠檬酸镁相关的专利（医药）

登录后查看更多信息

504

项与柠檬酸镁相关的文献（医药）

2024-10-01·Therapeutic Apheresis and Dialysis

Factors affecting clinical outcomes of continuous and intermittent plasmapheresis in patients with severe hypertriglyceridemia

Article

作者: Hussein, Eiman A.

AbstractIntroductionAcute hypertriglyceridemia is considered a category III indication for plasmapheresis. The use of plasma as replacement fluid (RF) has been suggested to replace the consumed lipoprotein lipase. Heparin when used as an anticoagulant could possibly release lipoprotein lipase, thereby increasing triglyceride clearance.MethodsThe impact of RF (albumin vs fresh frozen plasma (FFP) and anticoagulant (ACD‐A vs. heparin) on triglycerides following plasmapheresis in 27 patients with severe hypertriglyceridemia (SHTG) was investigated. A paired study of four patients with recurrent SHTG was conducted, evaluating continuous (Optia) versus intermittent flow plasmapheresis (Haemonetics).ResultsShorter procedures positively impacted triglycerides (TG) drop post‐sessions p < 0.05. In albumin sessions, patients who used heparin demonstrated significantly greater drop in TG and required less sessions than did those with citrate p < 0.05. In heparin sessions, patients who used albumin demonstrated significantly greater drop in triglycerides and required less sessions than did those with FFP p < 0.05. Three of six patients who used FFP and heparin showed a triglyceride drop of 11.7% following three sessions and a 50% drop with one albumin session. Compared with Haemonetics, Optia removed comparable volumes of plasma in less time, processing smaller blood volumes and using less citrate p < 0.05. Patients demonstrated significantly lower drop in TG and required more sessions with Haemonetics than they did with Optia p < 0.05.ConclusionShorter procedure was the main predictor for effective TG clearance. This can be achieved by continuous apheresis technology, particularly when using albumin as RF. TG removal via Optia seems to be optimized by using heparin.

2024-09-01·Advanced Healthcare Materials

Metabolic Control During Macrophage Polarization by a Citrate‐Functionalized Scaffold for Maintaining Bone Homeostasis

Article

作者: Hong, Chuhang ; Wei, Wenying ; Xia, Yuhao ; Wu, Xiaopei ; Dai, Honglian ; Zhao, Yanan ; Zheng, Dian

AbstractMetabolites, as markers of phenotype at the molecular level, can regulate the function of DNA, RNA, and proteins through chemical modifications or interactions with large molecules. Citrate is an important metabolite that affects macrophage polarization and osteoporotic bone function. Therefore, a better understanding of the precise effect of citrate on macrophage polarization may provide an effective alternative strategy to reverse osteoporotic bone metabolism. In this study, a citrate functional scaffold to control the metabolic pathway during macrophage polarization based on the metabolic differences between pro‐inflammatory and anti‐inflammatory phenotypes for maintaining bone homeostasis, is fabricated. Mechanistically, only outside M1 macrophages are accumulated high concentrations of citrate, in contrast, M2 macrophages consume massive citrate. Therefore, citrate‐functionalized scaffolds exert more sensitive inhibitory effects on metabolic enzyme activity during M1 macrophage polarization than M2 macrophage polarization. Citrate can block glycolysis‐related enzymes by occupying the binding‐site and ensure sufficient metabolic flux in the TCA cycle, so as to turn the metabolism of macrophages to oxidative phosphorylation of M2 macrophage, largely maintaining bone homeostasis. These studies indicate that exogenous citrate can realize metabolic control of macrophage polarization for maintaining bone homeostasis in osteoporosis.

2024-08-01·Journal of Clinical Sleep Medicine

Magnesium citrate monotherapy improves restless legs syndrome symptoms and multiple suggested immobilization test scores in an open-label pilot study

Article

作者: Gorantla, Sasikanth ; Ravisankar, Ashwath ; Trotti, Lynn Marie

STUDY OBJECTIVESAn estimated 3% of the population has clinically significant restless legs syndrome. Given the limited pharmacological options in the arsenal, there is a need for a therapeutic agent with a better side effect profile.METHODSTwelve treatment naive adults (10 women and 2 men with a median age of 41.5 [32-48.5] years) with primary restless legs syndrome were recruited in our open-label pilot study; magnesium citrate 200 mg was administered daily for 8 weeks. Serum magnesium levels, International Restless Legs Syndrome Study Group Rating Scale, Kohnen quality of life scale, and multiple suggested immobilization tests (three 1-hour tests) were performed before and after supplementation. Paired t tests and Wilcoxon signed-rank tests were used for data analysis. Pearson and Spearman's analyses assessed the association between magnesium levels and restless legs syndrome variables.RESULTSParticipants had a significant reduction in International Restless Legs Syndrome Study Group Rating Scale scores (6.67 [2.33-11] P = .006) and improved Kohnen quality of life scores (8.5 [2.09-14], P = .014) without notable differences in serum magnesium levels (P = .3). The median periodic limb movements during wakefulness index (30.40 [5.20, 122.40] to 8.63 [0.32, 17.47] P = .043) and self-reported discomfort score (19 [14, 30.5] to 6 [0, 8] P = .0010) of all 3 multiple suggested immobilization test trials also demonstrated improvement. Serum magnesium levels negatively correlated with multiple suggested immobilization test self-reported scores and the periodic limb movements during wakefulness indices.CONCLUSIONSDespite the limitations of open-label design, our study's positive results indicate the need for a placebo-controlled trial with a larger sample size.CLINICAL TRIAL REGISTRATIONRegistry: ClinicalTrials.gov; Name: The Effect of Magnesium Citrate Supplementation in Restless Legs Syndrome (RLS); URL: https://clinicaltrials.gov/ct2/show/study/NCT04462796; Identifier: NCT04462796.CITATIONGorantla S, Ravisankar A, Trotti LM. Magnesium citrate monotherapy improves restless legs syndrome symptoms and multiple suggested immobilization test scores in an open-label pilot study. J Clin Sleep Med. 2024;20(8):1357-1361.

100 项与柠檬酸镁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03265	柠檬酸镁	-	DB11110

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肠道准备	日本	Horii Pharmaceutical Ind., LTD.	1973-04-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性高血压	临床3期	日本	RMJ Holdings, Inc.	2022-01-30
高血压	临床2期	-	RMJ SGRpA	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02977286 (CTgov)	临床4期	便秘	12	Polyethylene Glycols+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Naloxegol Oral Tablet+Methylnaltrexone (Naloxegol Oral Tablet)	膚選衊鑰夢鹹淵範構艱(繭襯遞衊築淵壓觸壓餘) = 糧齋壓顧築廠範顧鑰餘遞繭積齋簾淵艱鹽餘窪 (簾積鬱淵憲鏇選襯蓋築, 艱鏇餘積觸網築獵鹽繭 ~ 廠夢壓衊範糧製願艱餘) 更多	-	2023-02-16
NCT02977286 (CTgov)	临床4期	便秘	12	Placebo Oral Tablet+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Methylnaltrexone (Placebo Oral Tablet)	膚選衊鑰夢鹹淵範構艱(繭襯遞衊築淵壓觸壓餘) = 鏇積餘鏇網製願餘衊製遞繭積齋簾淵艱鹽餘窪 (簾積鬱淵憲鏇選襯蓋築, 顧淵積廠築繭憲觸艱艱 ~ 壓觸蓋願範餘顧窪艱遞) 更多	-	2023-02-16
WCN2015	N/A	2型糖尿病	100	Magnesium dicitrate	築鹹蓋鏇艱簾廠遞淵蓋(壓鏇糧艱鑰網鑰憲觸壓) = 齋廠窪淵製夢夢遞積積網願遞襯蓋艱鑰蓋糧糧 (積襯獵窪鏇獵憲積窪構 )	-	2015-10-15